At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 4 enrolled
Drug / intervention
Budesonidedrug
Likely dose
Budesonide 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Detect Oral Administration of Budesonide in Women.
In Brief
A Phase 1 clinical trial evaluating Budesonide for Healthy. Completed, enrolled 4 participants across 1 site.
Detailed Summary
This study aims at identifying analysis strategies to detect oral administration of Budesonide in women; in order for them to be used by the accredited laboratories of the Worl Anti-Doping Agency (WADA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSpain
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedMay 2018
Primary CompletionJul 2018
Study CompletionSep 2018
TodayJul 2026
First PostedMay 25, 2018
Enrollment StartMay 22, 2018
Primary CompletionJul 1, 2018
Study CompletionSep 10, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 8.1 years ago
Interventions
Budesonidedrug
Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.